Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Best practice--ongoing polemics.

R Paoletti1, S Bellosta

  • 1Istituto di Scienze Farmacologiche, Facoltà di Farmacia, Università di Milano, Italy.

Atherosclerosis
|June 26, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential effects of traditional cigarette, electronic cigarette, and tobacco heating product on human vascular smooth muscle cell phenotypic switch: A comparative functional perspective.

Atherosclerosis·2025
Same author

Simvastatin ameliorates senescence-induced mitochondrial dysfunction in vascular smooth muscle cells.

Atherosclerosis·2025
Same author

Search for Gamma-Ray Spectral Lines from Dark Matter Annihilation up to 100 TeV toward the Galactic Center with MAGIC.

Physical review letters·2023
Same author

Observation of Rayleigh-Lamb waves generated by the 2022 Hunga-Tonga volcanic eruption with the POLA detectors at Ny-Ålesund.

Scientific reports·2022
Same author

Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review.

Cardiovascular drugs and therapy·2022
Same author

Large-Area SiPM Pixels (LASiPs): A cost-effective solution towards compact large SPECT cameras.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2021
Same journal

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Atherosclerosis·2026
Same journal

Causal insights of modifiable cardiovascular risk factors for dementia risk - potential for efficient prevention and improved brain health.

Atherosclerosis·2026
Same journal

Serial OCT-based coronary physiology and plaque composition in vessels with nonobstructive coronary lesions following intensive lipid-lowering therapy: YELLOW III sub-study.

Atherosclerosis·2026
Same journal

Earliest age to detect lifetime cardiometabolic health stratification in children.

Atherosclerosis·2026
Same journal

Sympathetic neurons exacerbate atherosclerosis by modulating macrophage function via the NPY/Y1R axis.

Atherosclerosis·2026
Same journal

Optimizing lipoprotein(a) testing for immediate clinical impact in primary prevention.

Atherosclerosis·2026
See all related articles

Aggressive lipid-lowering therapy, particularly with statins, significantly reduces cardiovascular events and mortality in hyperlipidemia patients. These treatments are safe and effective, even for individuals with moderately elevated cholesterol levels.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Hyperlipidemia management involves various lipid-lowering drugs.
  • Early trials showed cholesterol reduction lowers ischemic cardiovascular event risk.
  • Statin trials demonstrate significant benefits in coronary heart disease (CHD) prevention, including mortality reduction.

Purpose of the Study:

  • To review current treatment strategies for hyperlipidemia.
  • To highlight the benefits of statin therapy in CHD prevention and mortality reduction.
  • To discuss the evolving targets for lipid modification and treatment initiation.

Main Methods:

  • Review of lipid-lowering trials, including early studies and landmark statin trials.
  • Analysis of evidence for lipid modification in reducing cardiovascular events.

Related Experiment Videos

  • Discussion of treatment thresholds and target levels for lipid-lowering therapy.

    • Main Results:

    • Lipid modification, especially with statins, significantly reduces cardiovascular event risk.
    • Statin therapy can lead to mortality reduction within the first year.
    • Aggressive lipid-lowering therapy achieves cholesterol goals safely and effectively, even in patients with moderate lipid abnormalities.

    Conclusions:

    • Statin therapy is well-tolerated and beneficial for patients with moderately raised cholesterol.
    • Aggressive lipid-lowering treatment can prevent or limit coronary artery disease events, including death and disability.
    • Current treatment goals for established CHD are achievable with aggressive lipid-lowering strategies.